Primary Liver Cancer

  • Higinia R. Cárdenes
  • Foster Lasley
Part of the Medical Radiology book series (MEDRAD)


Hepatocellular carcinoma (HCC) is the most frequently occurring primary tumor of the liver in adults and the fourth most common cause of cancer-related deaths in the world. Its rising incidence in the United States and Europe is attributed to the increased incidence of hepatitis C infection. Currently, the optimal treatment for HCC is orthotopic liver transplant or surgical resection for selected patients. However many patients are not able to undergo these radical interventions. Historically, radiotherapy for hepatocellular carcinoma has been shown to be poorly tolerated in the cirrhotic liver and has had suboptimal results with standard fractionation. With the introduction of stereotactic body radiotherapy (SBRT) techniques, there are emerging data indicating that the use of targeted, highly conformal, hypofractionated ablative radiotherapy can provide results that compare favorably with other ablative procedures for HCC in terms of local control, safety and survival. Therefore, SBRT is gaining interest as an alternative, safe, non-invasive and effective technique for the treatment of appropriately selected patients who are not able to undergo orthotopic liver transplantation.


Planning Target Volume Stereotactic Body Radiotherapy Gross Tumor Volume Barcelona Clinic Liver Cancer Internal Target Volume 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Conflict of Interest

There are no potential conflicts of interest among the authors and this manuscript. There are no financial or non-financial competing interests. This manuscript has been seen, read, and agreed upon in its content by all designated authors. This manuscript has not been submitted or published elsewhere.


  1. Abrams RA, Pajak TF, Haulk TL, Flam M, Asbell SO (1998) Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center. Cancer J Sci Am 4(3):178–184PubMedGoogle Scholar
  2. Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, Johnstone PA, Cardenes HR (2011) Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Rad Oncol Biol Phys 81(4):e447–e453CrossRefGoogle Scholar
  3. Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K, Yamada R (2000) Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 32(6):1224–1229PubMedCrossRefGoogle Scholar
  4. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, Keall P, Lovelock M, Meeks S, Papiez L, Purdie T, Sadagopan R, Schell MC, Salter B, Schlesinger DJ, Shiu AS, Solberg T, Song DY, Stieber V, Timmerman R, Tome WA, Verellen D, Wang L, Yin FF (2010) Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 37(8):4078–4101PubMedCrossRefGoogle Scholar
  5. Blomgren H, Lax I, Göranson H, Kræpelien T, Nilsson B, Näslund I, Svanström R, Tilikidis A (1998) Radiosurgery for tumors in the body: clinical experience using a new method. J Radiosurg 1(1):63–74CrossRefGoogle Scholar
  6. Bronowicki JP, Boudjema K, Chone L, Nisand G, Bazin C, Pflumio F, Uhl G, Wenger JJ, Jaeck D, Boissel P, Bigard MA, Gaucher P, Vetter D, Doffoel M (1996) Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma. J Hepatol 24(3):293–300PubMedCrossRefGoogle Scholar
  7. Bruix J, Boix L, Sala M, Llovet JM (2004) Focus on hepatocellular carcinoma. Cancer Cell 5(3):215–219PubMedCrossRefGoogle Scholar
  8. Bruix J, Sherman M (2011) American Association for the Study of Liver Diseases Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022. doi: 10.1002/hep.24199 PubMedCrossRefGoogle Scholar
  9. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J, EASL Panel of Experts on HCC (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference. European Association for the Study of the Liver. J Hepatol 35(3):421–430Google Scholar
  10. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208–1236Google Scholar
  11. Cao M, Cardenes H, Langer M, Slessinger E, Zhao Q, DesRosiers C (2008) Evaluation of automatic volume match function for kilovoltage cone-beam CT (CBCT) guided patient setup. Med Phys 35(6):2990Google Scholar
  12. Cárdenes H, Price T, Perkins S, Maluccio M, Kwo P, Breen T, Henderson M, Schefter T, Tudor K, Deluca J, Johnstone P (2010) Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 12(3):218–225. doi: 10.1007/s12094-010-0492-x PubMedCrossRefGoogle Scholar
  13. Carr BI, Kondragunta V, Buch SC, Branch RA (2010) Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 116(5):1305–1314PubMedCrossRefGoogle Scholar
  14. Cascales Campos P, Ramirez P, Gonzalez R, Febrero B, Pons JA, Miras M, Sanchez Bueno F, Robles R, Parrilla P (2011) Value of 18-FDG-positron emission tomography/computed tomography before and after transarterial chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: initial results. Transpl Proc 43(6):2213–2215CrossRefGoogle Scholar
  15. Chen M-S, Li J-Q, Zheng Y, Guo R-P, Liang HH, Zhang YQ, Lin XJ, Lau WY (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243(3):321–328PubMedCrossRefGoogle Scholar
  16. Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang T-S, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25–34PubMedCrossRefGoogle Scholar
  17. Cheng JC-H, Wu JK, Huang CM, Huang DY, Cheng SH, Lin YM, Jian JJ, Yang PS, Chuang VP, Huang AT (2002) Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. Radiother Oncol 63(1):41–45PubMedCrossRefGoogle Scholar
  18. Cho YK, Kim JK, Kim MY, Rhim H, Han JK (2009) Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 49(2):453–459PubMedCrossRefGoogle Scholar
  19. Choi BO, Choi IB, Jang HS, Kang YN, Jang JS, Bae SH, Yoon SK, Chai GY, Kang KM (2008) Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer 8:351PubMedCrossRefGoogle Scholar
  20. Choi BO, Jang HS, Kang KM, Lee SW, Kang YN, Chai GY, Choi IB (2006) Fractionated stereotactic radiotherapy in patients with primary hepatocellular carcinoma. Jpn J Clin Oncol 36(3):154–158PubMedCrossRefGoogle Scholar
  21. Chok KS, Ng KK, Poon RTP, Lam CM, Yuen J, Tso WK, Fan ST (2006) Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization. Arch Surg 141(12):1231–1236PubMedCrossRefGoogle Scholar
  22. Christensen E (2004) Prognostic models including the Child-Pugh, MELD and Mayo risk scores–where are we and where should we go? J Hepatol 41(2):344–350PubMedCrossRefGoogle Scholar
  23. CLIP (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28(3):751–755CrossRefGoogle Scholar
  24. Dawson LA, Eccles C, Bissonnette J-P, Brock KK (2005) Accuracy of daily image guidance for hypofractionated liver radiotherapy with active breathing control. Int J Rad Oncol Biol Phys 62(4):1247–1252CrossRefGoogle Scholar
  25. Dawson LA, McGinn CJ, Normolle D, Ten Haken RK, Walker S, Ensminger W, Lawrence TS (2000) Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 18(11):2210–2218PubMedGoogle Scholar
  26. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK (2002) Analysis of radiation-induced liver disease using the Lyman NTCP model.[Erratum appears in Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1422]. Int J Rad Oncol Biol Phys 53 (4):810-821Google Scholar
  27. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2009) AJCC cancer staging manual, 7th edn. Springer, New YorkGoogle Scholar
  28. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247PubMedCrossRefGoogle Scholar
  29. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update.[Erratum appears in Ann Intern Med. 2004 Jan 20;140(2):151].[Summary for patients in Ann Intern Med. 2003 Nov 18;139(10):I28; PMID: 14623640]. Ann Intern Med 139(10):817–823Google Scholar
  30. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917.
  31. Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, Reig M, Bianchi L, Llovet JM, Bruix J (2009) Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115(3):616–623PubMedCrossRefGoogle Scholar
  32. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Bru C, Bruix J (2008) Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. [Erratum appears in Hepatology. 2008 Feb;47(2):769]. Hepatology 47(1):97–104Google Scholar
  33. Fuss M, Salter BJ, Rassiah P, Cheek D, Cavanaugh SX, Herman TS (2004) Repositioning accuracy of a commercially available double-vacuum whole body immobilization system for stereotactic body radiation therapy. Technol Cancer Res Treat 3(1):59–67PubMedGoogle Scholar
  34. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgro G, Burroughs AK (2010) Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 52(3):380–388PubMedCrossRefGoogle Scholar
  35. Herfarth KK, Debus J, Lohr F, Bahner ML, Rhein B, Fritz P, Hoss A, Schlegel W, Wannenmacher MF (2001) Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 19(1):164–170PubMedGoogle Scholar
  36. Herfarth KK, Hof H, Bahner ML, Lohr F, Hoss A, van Kaick G, Wannenmacher M, Debus J (2003) Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. Int J Rad Oncol Biol Phys 57(2):444–451CrossRefGoogle Scholar
  37. International Commission on Radiation Units and Measurements (ICRU) (1993) Prescribing, recording and reporting photon beam therapy. vol Report 50. ICRU, Bethesda, MDGoogle Scholar
  38. International Commission on Radiation Units and Measurements (ICRU) (1999) Prescribing, recording and reporting photon beam therapy; supplement to ICRU Report No. 50, vol Report 62. ICRU, Bethesda, MDGoogle Scholar
  39. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, Dickson ER, Kim WR (2001) A model to predict survival in patients with end-stage liver disease. Hepatology 33(2):464–470PubMedCrossRefGoogle Scholar
  40. Kim DY, Park W, Lim DH, Lee JH, Yoo BC, Paik SW, Kho KC, Kim TH, Ahn YC, Huh SJ (2005) Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 103(11):2419–2426PubMedCrossRefGoogle Scholar
  41. Kim JW, Seong J, Jun M, Lee IJ, Yoon HI, Cho HJ, Han KH (2011) Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy. Int J Rad Oncol Biol Phys 47(22):6368–6370Google Scholar
  42. Kornberg A, Küpper B, Tannapfel A, Büchler P, Krause B, Witt U, Gottschild D, Friess H (2011) Patients with (18) F-FDG non-avid advanced HCC on clinical staging may achieve recurrence-free long-term survival after liver transplantation. Liver Transpl. doi: 10.1002/lt.22416 Google Scholar
  43. Kwon JH, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, Choi JY, Yoon SK, Chung KW (2010) Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 10:475PubMedCrossRefGoogle Scholar
  44. Lawrence TS, Ten Haken RK, Kessler ML, Robertson JM, Lyman JT, Lavigne ML, Brown MB, DuRoss DJ, Andrews JC, Ensminger WD et al (1992) The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Rad Oncol Biol Phys 23(4):781–788CrossRefGoogle Scholar
  45. Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, Bartolozzi C (2005) Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology 234(3):961–967PubMedCrossRefGoogle Scholar
  46. Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB, Kao CH (2011) 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: A systematic review and meta-analysis. Eur J RadiolGoogle Scholar
  47. Liu LX, Jiang HC, Piao DX (2002) Radiofrequence ablation of liver cancers. World J Gastroenterol 8(3):393–399PubMedGoogle Scholar
  48. Liu MT, Li SH, Chu TC, Hsieh CY, Wang AY, Chang TH, Pi CP, Huang C–C, Lin JP (2004) Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization. Jpn J Clin Oncol 34(9):532–539PubMedCrossRefGoogle Scholar
  49. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37(2):429–442PubMedCrossRefGoogle Scholar
  50. Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30(6):1434–1440PubMedCrossRefGoogle Scholar
  51. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J, Barcelona Liver Cancer G (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734–1739PubMedCrossRefGoogle Scholar
  52. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz J-F, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, Group SIS (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378–390Google Scholar
  53. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, Poulin-Costello M, Moscovici M, Voliotis D, Bruix J, For the SHARP Investigators Study Group (2007) Sorafenib improves survival in advanced hepatocellular carcinoma: results of a phase III randomized placebo-controlled trial: 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 25:LBA1 (18S)Google Scholar
  54. Lo SS, Dawson LA, Kim EY, Mayr NA, Wang JZ, Huang Z, Cardenes HR (2010) Stereotactic body radiation therapy for hepatocellular carcinoma. Discov 9(48):404–410Google Scholar
  55. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11):693–699PubMedCrossRefGoogle Scholar
  56. Mendez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJM, Nowak PCJM, Nuyttens JJ, Brandwijk RP, Verhoef C, Ijzermans JNM, Levendag PC (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 45(7):831–837PubMedCrossRefGoogle Scholar
  57. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214PubMedCrossRefGoogle Scholar
  58. Mornex F, Girard N, Beziat C, Kubas A, Khodri M, Trepo C, Merle P (2006) Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies–mature results of the French Phase II RTF-1 trial. Int J Rad Oncol Biol Phys 66(4):1152–1158CrossRefGoogle Scholar
  59. Nicolini A, Martinetti L, Crespi S, Maggioni M, Sangiovanni A (2010) Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 21(3):327–332PubMedCrossRefGoogle Scholar
  60. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56(4):918–928PubMedCrossRefGoogle Scholar
  61. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M (2009) Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 104(2):514–524PubMedCrossRefGoogle Scholar
  62. Papiez L, Timmerman R, DesRosiers C, Randall M (2003) Extracranial stereotactic radioablation: physical principles. Acta Oncol 42(8):882–894PubMedCrossRefGoogle Scholar
  63. Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO (2002) Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Rad Oncol Biol Phys 54(1):150–155CrossRefGoogle Scholar
  64. Poon RTP, Ng KKC, Lam C-M, Ai V, Yuen J, Fan S-T (2004) Effectiveness of radiofrequency ablation for hepatocellular carcinomas larger than 3 cm in diameter. Arch Surg 139(3):281–287PubMedCrossRefGoogle Scholar
  65. Potters L, Steinberg M, Rose C, Timmerman R, Ryu S, Hevezi JM, Welsh J, Mehta M, Larson DA, Janjan NA, American Society for Therapeutic R, Oncology, American College of R (2004) American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Rad Oncol Biol Phys 60(4):1026–1032Google Scholar
  66. Price TR, Perkins SM, Sandrasegaran K, Henderson MA, Maluccio MA, Zook JE, Tector AJ, Vianna RM, Johnstone PA, Cardenes HR (2011) Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer. doi: 10.1002/cncr.26404 Google Scholar
  67. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60(8):646–649PubMedCrossRefGoogle Scholar
  68. Robertson JM, Lawrence TS, Dworzanin LM, Andrews JC, Walker S, Kessler ML, DuRoss DJ, Ensminger WD (1993) Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy. J Clin Oncol 11(7):1286–1293PubMedGoogle Scholar
  69. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE (2009) Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27(10):1572–1578PubMedCrossRefGoogle Scholar
  70. Salem R, Hunter RD (2006) Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: a review. Int J Rad Oncol Biol Phys 66:S83–S88CrossRefGoogle Scholar
  71. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138(1):52–64PubMedCrossRefGoogle Scholar
  72. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, Morabito A, De Franchis R, Colombo M (2004) Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126(4):1005–1014PubMedCrossRefGoogle Scholar
  73. Seo YS, Kim MS, Yoo SY, Cho CK, Choi CW, Kim JH, Han CJ, Park SC, Lee BH, Kim YH, Lee DH (2010) Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 102(3):209–214PubMedCrossRefGoogle Scholar
  74. Seong J, Park HC, Han KH, Chon CY (2003) Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Rad Oncol Biol Phys 55(2):329–336CrossRefGoogle Scholar
  75. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T, Omata M (2005) A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129(1):122–130PubMedCrossRefGoogle Scholar
  76. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212–236PubMedCrossRefGoogle Scholar
  77. Silva MA, Hegab B, Hyde C, Guo B, Buckels JAC, Mirza DF (2008) Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 57(11):1592–1596PubMedCrossRefGoogle Scholar
  78. Son SH, Choi BO, Ryu MR, Kang YN, Jang JS, Bae SH, Yoon SK, Choi IB, Kang KM, Jang HS (2010) Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Rad Oncol Biol Phys 78(4):1073–1080CrossRefGoogle Scholar
  79. Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK (2007) Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 33:437–447PubMedCrossRefGoogle Scholar
  80. Stillwagon GB, Order SE, Guse C, Klein JL, Leichner PK, Leibel SA, Fishman EK (1989) 194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study. Int J Rad Oncol Biol Phys 17(6):1223–1229CrossRefGoogle Scholar
  81. Takayasu K (2010) Chemoembolization for unresectable hepatocellular carcinoma in Japan. Oncology 78(Suppl 1):135–141PubMedCrossRefGoogle Scholar
  82. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216PubMedCrossRefGoogle Scholar
  83. Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA (2008) Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. [Erratum appears in J Clin Oncol. 2008 Aug 10, 26(23), pp 3911–3912]. J Clin Oncol 26(4):657–664PubMedCrossRefGoogle Scholar
  84. Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J (1992) Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 16(2):353–357PubMedCrossRefGoogle Scholar
  85. Wulf J, Hadinger U, Oppitz U, Olshausen B, Flentje M (2000) Stereotactic radiotherapy of extracranial targets: CT-simulation and accuracy of treatment in the stereotactic body frame. Radiother Oncol 57(2):225–236PubMedCrossRefGoogle Scholar
  86. Yin XY, Xie XY, Lu MD, Xu HX, Xu ZF, Kuang M, Liu G-J, Liang J-Y, Lau WY (2009) Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term outcome and prognostic factors. Cancer 115(9):1914–1923PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of Clinical Radiation OncologyIndiana University School of MedicineIndianapolisUSA

Personalised recommendations